aclidinium vs benralizumab
Side-by-side comparison of aclidinium and benralizumab Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Fasenra
Duaklir Pressair is a combination medicine used to help people with COPD breathe better. It contains two medicines that open up the airways in your lungs.
Fasenra is a medicine that can help treat severe asthma and EGPA. It works by lowering the number of eosinophils in your blood, which can reduce swelling in your lungs and blood vessels.
Duaklir Pressair is used to treat chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that makes it hard to breathe. This medicine helps to open the airways and make it easier to breathe for people with COPD.
Fasenra is used to treat severe asthma in adults and children 6 years and older when used with other asthma medicines. It is for people whose asthma is caused by too many eosinophils (a type of white blood cell). Fasenra also treats adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare disease that causes blood vessel inflammation.
Duaklir Pressair contains two medicines that work in different ways. One medicine relaxes the muscles around your airways, opening them up. The other medicine prevents the muscles from tightening.
Fasenra is a special type of antibody that targets a protein called interleukin-5 receptor alpha (IL-5Rα). This protein is found on the surface of eosinophils. By attaching to this protein, Fasenra helps to lower the number of eosinophils in your blood.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Headache
- • Sore throat
- • Fever
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
- Asthma 2,775
- Difficulty breathing 1,802
- Death 1,437
- Medicine not working 1,418
- Cough 944
LABAs, such as formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, increase the risk of asthma-related death. Duaklir Pressair is not for asthma. Do not use Duaklir Pressair if you are allergic to milk proteins or any of the ingredients in it. Tell your doctor if you have heart problems, glaucoma, trouble urinating, diabetes, or seizures.
Serious allergic reactions can happen after you get a Fasenra shot. Tell your doctor right away if you have any signs of an allergic reaction, such as hives, swelling, or trouble breathing. Do not stop taking your steroid medicines suddenly when you start Fasenra. Your doctor will lower your steroid dose slowly, if needed. If you have a parasitic infection, it should be treated before you start Fasenra.
It is not known if Duaklir Pressair will harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if this medicine passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Duaklir Pressair.
There is not enough information to know if Fasenra will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if Fasenra passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Fasenra.
Also Compare — Nearby Drugs
Compare aclidinium with
How to Read This aclidinium vs benralizumab Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while benralizumab sits within the Anti-IL-5R Monoclonal Antibody class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while benralizumab has 8,376. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between aclidinium and benralizumab — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.